This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xiao, Z. Articles by Ali, I. U. Search for Related Content PubMed PubMed Citation Articles by Xiao, Z. Articles by Ali, I. U.

Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors

¹ Laboratory of Proteomics and Analytical Technologies and ² Advanced Biomedical Computing Center, SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, Maryland; ³ Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland; ⁴ University of Texas M. D. Anderson Cancer Center, Houston, Texas; and ⁵ Imperial Cancer Research Fund, St. Mark’s Hospital, London, United Kingdom

Cyclooxygenase-2 is a valid target for cancer prevention and treatment. This has been shown in preclinical and clinical cancer prevention studies by using a cyclooxygenase-2 inhibitor, celecoxib. When used in a randomized cancer prevention clinical trial on patients with the inherited autosomal dominant condition, familial adenomatous polyposis, celecoxib proved efficacious. However, a remarkable heterogeneity in patients’ responses to the chemopreventive effects of celecoxib was observed. Proteomic profiling of sera from these patients identified several markers, the expression of which was specifically modulated after treatment with celecoxib. A decision tree algorithm identified classifiers for response to celecoxib with relatively high sensitivity but moderate to low specificity. In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose.

This article has been cited by other articles:

				P. J. O'Dwyer, S. G. Eckhardt, D. G. Haller, J. Tepper, D. Ahnen, S. Hamilton, A. B. Benson III, M. Rothenberg, N. Petrelli, H.-J. Lenz, et al. Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups J. Clin. Oncol., June 1, 2007; 25(16): 2313 - 2321. [Abstract] [Full Text] [PDF]

				C. S. Tan, A. Ploner, A. Quandt, J. Lehtio, and Y. Pawitan Finding regions of significance in SELDI measurements for identifying protein biomarkers Bioinformatics, June 15, 2006; 22(12): 1515 - 1523. [Abstract] [Full Text] [PDF]

				E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]

				R. J. Robbins, J. Villanueva, and P. Tempst Distilling Cancer Biomarkers From the Serum Peptidome: High Technology Reading of Tea Leaves or an Insight to Clinical Systems Biology? J. Clin. Oncol., August 1, 2005; 23(22): 4835 - 4837. [Full Text] [PDF]

				S. M. Lippman and B. Levin Cancer Prevention: Strong Science and Real Medicine J. Clin. Oncol., January 10, 2005; 23(2): 249 - 253. [Full Text] [PDF]

				E. T. Hawk and B. Levin Colorectal Cancer Prevention J. Clin. Oncol., January 10, 2005; 23(2): 378 - 391. [Abstract] [Full Text] [PDF]